General health checks,
does it really help with Prevention of ischaemic heart disease and death in asymptomatic general adults?
research showsRoutine general health checks for asymptomatic adults are rated F. Cochrane included 17 trials, with outcome reporting from 15 trials and 251,891 participants. By outcome, total mortality was null in 11 trials with 233,298 participants, RR 1.00 (95% CI 0.97 to 1.03), while ischaemic heart disease was null in four trials with 164,881 participants, RR 0.98 (95% CI 0.94 to 1.03).
ads claimMarketing may imply that undergoing many tests every year prevents myocardial infarction and premature death, and that more test items necessarily extend healthy life. A general check package offered to asymptomatic populations did not reduce ischaemic heart disease or total mortality. Value should be assessed separately for individual risk, evidence-based screening for a specific condition, and effective treatment after an abnormal finding.
Useful facts when choosing a product
- A general health check here means a package using multiple tests to screen for diseases or risk factors across more than one organ system; it is different from diagnostic testing prompted by symptoms.
- Follow-up testing and treatment for a person with established abnormal blood pressure, glucose, lipids, or another diagnosed condition are outside this verdict.
- Individual programs with their own direct evidence, such as selected cancer screening or abdominal aortic aneurysm screening based on age, sex, smoking, or family history, require separate assessment.
- Checks can lead to additional testing, incidental findings, overdiagnosis, and unnecessary treatment, so test selection should reflect personal risk and expected benefits and harms.
What the research actually shows
Inter99 randomized 59,616 people, 11,629 to screening and 47,987 to control, and analyzed 58,308. Ten-year ischaemic heart disease was HR 1.03 (95% CI 0.94 to 1.13), and total mortality was HR 1.00 (95% CI 0.91 to 1.09). The funding list names Novo Nordisk, the company, not the Novo Nordisk Foundation. The article states that sponsors had no role in design, conduct, analysis, or interpretation. Krogsboll 2019 included 17 trials, with outcomes reported from 15 trials and 251,891 participants. Total mortality was RR 1.00 (95% CI 0.97 to 1.03) in 11 trials with 233,298 participants; ischaemic heart disease was RR 0.98 (95% CI 0.94 to 1.03) in four trials with 164,881 participants.
Why this is classified as F (8)
Inter99 randomized 59,616 and analyzed 58,308 participants, with null ischaemic heart disease and total mortality. Cochrane found null total mortality in 11 trials with 233,298 participants and null ischaemic heart disease in four trials with 164,881 participants, supporting F with 8 points.
Counterpoint. Instead of rejecting every check, evidence-based individual screening, vaccination, blood-pressure measurement, and risk-factor counseling should be selected according to age and personal risk. Chest pain, shortness of breath, neurological symptoms, unexplained weight loss, or other concerning symptoms warrant diagnostic assessment rather than waiting for a routine check.
Rejudgment record. Cross-check applied — Applied failure of the prespecified ischaemic-heart-disease primary endpoint in a large population trial and high-certainty repeated null findings for total mortality and ischaemic heart disease in Cochrane as direct disconfirming evidence. F is reserved for repeated failure in the same indication, which is met here for general health-check packages in asymptomatic populations
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prevention of fatal and nonfatal ischaemic heart disease | F | The Inter99 primary endpoint failed, and the pooled Cochrane result from four trials with 164,881 participants was also null with high certainty. |
| Prevention of all-cause mortality | F | Inter99 reported HR 1.00, and 11 Cochrane trials with 233,298 participants reported RR 1.00, showing repeated failure in the same indication. |
| Prevention of cardiovascular mortality | F | Across nine Cochrane trials with 170,227 participants, RR was 1.05 (95% CI 0.94 to 1.16), with no benefit. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Jørgensen T et al. 2014 Inter99 | Population-based randomized controlled trial with ten-year registry follow-up | 58,308 | Danish Research Councils, Health Foundation, Danish Centre for Evaluation and Health Technology Assessment, Copenhagen County, Danish Heart Foundation, Ministry of Health and Prevention, Association of Danish Pharmacies, Augustinus Foundation, Novo Nordisk company, Velux Foundation, Becket Foundation, and Ib Henriksens Foundation; sponsors had no role in design, conduct, analysis, or interpretation | Primary endpoint of ten-year fatal and nonfatal ischaemic heart disease; secondary endpoints of stroke, combined events, and total mortality | Primary endpoint failed: 2,782 events, HR 1.03 (95% CI 0.94 to 1.13), Gray test P=.30; total mortality was also null, HR 1.00 (95% CI 0.91 to 1.09). | Key large direct hard-outcome disconfirming trial |
| Krogsbøll LT et al. 2019 Cochrane review | Systematic review and meta-analysis of randomized trials | 164,881 | Salary and facilities from the Nordic Cochrane Centre and partial salary support from Trygfonden, Denmark; all three authors declared no conflicts | Total, cardiovascular, and cancer mortality and fatal and nonfatal ischaemic heart disease and stroke | Total mortality RR 1.00 (95% CI 0.97 to 1.03, I-squared=0%) and ischaemic heart disease RR 0.98 (95% CI 0.94 to 1.03, I-squared=11%) were both null with high certainty. | Independent repeated disconfirmation in the same indication |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] General health checks x prevention of ischaemic heart disease and death — Evidence Grade F·8. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/general/general-health-check-ischaemic-heart-disease-mortality-prevention/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.